Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 135.00Impact Factor 2024: 2.2
Concentrating on molecular biomarkers in cancer research, Cancer Biomarkers publishes original research findings (and reviews solicited by the editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion.
The disease markers may include, but are not limited to, genomic, epigenomic, proteomics, cellular and morphologic, and genetic factors predisposing to the disease or indicating the occurrence of the disease. Manuscripts on these factors or biomarkers, either in altered forms, abnormal concentrations or with abnormal tissue distribution leading to disease causation will be accepted.
Authors: Yang, Liu | Wang, Tiejun | Zhang, Jun | Wang, Xuxia
Article Type: Research Article
Abstract: BACKGROUND: Epithelial-mesenchymal transition (EMT) is a complicated process that has been implicated in cancer progression and metastasis as well as the formation of many tissues and organs. BTB/POZ domain-containing protein 7 (BTBD7) is reported to regulate transcriptional factors and involved in the process of invasion and metastasis of some malignant tumors. Additionally, our preliminary studies have confirmed that BTBD7 expression was significantly correlated with Slug expression and poor prognosis of primary salivary adenoid cystic carcinoma (SACC). On this basis, this study further investigated function of BTBD7 in the invasion and metastasis of SACC in vitro , which may be …a possible target of gene therapy in the future. METHODS: The expression of BTBD7 and Slug were both examined in SACC-LM and SACC-83 cell lines by immunofluorescence staining. High invasive SACC-LM cells were transfected with BTBD7 siRNA and the expression levels of BTBD7 and Slug were detected in both gene and protein levels by qRT-PCR and western blot analysis. Assays were performed to survey cell migration, invasion and proliferation capabilities with BTBD7 silencing. RESULTS: BTBD7 and Slug proteins were detected in SACC-LM and SACC-83 cell lines. BTBD7 silencing down-regulated the expression of Slug and MMP9 meanwhile up-regulated the expression of E-cadherin in SACC-LM cells, the migration and invasion abilities of cells were obviously suppressed but with no influence on cell proliferation. CONCLUSIONS: BTBD7 silencing inhibited EMT through regulation of Slug expression in SACC-LM cells and might act as a potential molecular target for gene therapy of SACC. Show more
Keywords: BTBD7, Slug, salivary adenoid cystic carcinoma, RNA interference
DOI: 10.3233/CBM-170262
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 461-468, 2017
Authors: Zhao, Ping | Meng, Meng | Xu, Bin | Dong, Aiping | Ni, Guangzhen | Lu, Lianfang
Article Type: Research Article
Abstract: MUC1, a membrane tethered mucin glycoprotein, is overexpressed in > 60% of human pancreatic cancers (PCs), and is associated with poor prognosis and enhanced metastasis. Here, we report the effect of silencing MUC1 expression on the growth, migration and invasive ability of pancreatic cancer cells, and explored its mechanisms. We observed that siRNA mediated suppression of the MUC1 expression significantly reduced invasive and migrative capability and induced apoptosis of the pancreatic cancer PANC-1 cells. We found that Slug was inhibited in the MUC1 siRNA transfected PANC-1 cells (MUC1 siRNA/PANC-1 cells). Expression of PUMA and E-cadherin was increased …in the MUC1 siRNA/PANC-1 cells. PANC-1 cells overexpressing full long Slug gene (when transfected with Slug cDNA plasmid) significantly inhibited PUMA and E-cadherin expression in the MUC1 siRNA/PANC-1 cells. Silencing PUMA expression inhibited apoptosis in the MUC1 siRNA transfected PANC-1 cells (MUC1 siRNA/PANC-1 cells). Silencing E-cadherin expression restored the invasion and migration ability in the MUC1 siRNA/PANC-1 cells. We therefore concluded that silencing MUC1 expression inhibited migration and invasion, and induced apoptosis of PANC-1 cells via downregulation of Slug and upregulation of Slug dependent PUMA and E-cadherin expression. MUC1 could serve as a potential therapeutic target in pancreatic cancer. Show more
Keywords: Pancreatic cancer, invasion, MUC1, Slug
DOI: 10.3233/CBM-170297
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 469-476, 2017
Authors: Kim, Soo-Jin | Kim, Eunhee | Rim, Kyung-Taek
Article Type: Research Article
Abstract: Testing carcinogenicity caused by chemicals requires a noninvasive tool that can be used before autopsy because autopsy takes a long time. We investigated whether non-small cell lung cancer related gene mutations could be detected in cell-free DNA in plasma by Insight Onco TM next-generation sequencing, which is a fast and sensitive method. Adenoma formation was confirmed in urethane-injected 17-week-old mice. Seven single nucleotide polymorphisms, such as Cdkn2a and Vegfa, were selected. Mutant-enriched Insight Onco TM NGS and normal NGS were performed on genomic DNA. The results demonstrate that …Insight Onco TM NGS detected Cdkn2a and Vegfa SNPs at 0.05%. The sensitivity of Insight Onco TM NGS was twice higher than that of normal NGS. In this analysis, the Cdkn2a gene mutation was detected not only in two genomic DNA samples of lung tissue from the 11th week of urethane injection but also in two cell-free DNA samples. In addition, the Vegfa gene mutation was detected not only in three genomic DNA samples of lung tissue of injection but also in one cell-free DNA sample, showing 33% concordance. Our results confirm that Insight Onco TM NGS is a rapid and sensitive detection method that enables lung cancer-associated gene mutations to be detected in cell-free DNA before the end of the carcinogenicity test. Show more
Keywords: Cell-free DNA, lung tumor, non-invasive, plasma, quantification
DOI: 10.3233/CBM-170303
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 477-485, 2017
Authors: Chen, Jing | Cao, Shun-Wang | Cai, Zhen | Zheng, Lei | Wang, Qian
Article Type: Research Article
Abstract: BACKGROUND: Epithelial-mesenchymal transition (EMT) plays a crucial role in circulating tumor cells (CTCs) dissemination and cancer metastasis. OBJECTIVE: To investigate the EMT phenotypes of CTCs in hepatocellular carcinoma (HCC) patients and the clinical utility in the early diagnosis of HCC metastasis and progression. METHODS: We retrospectively analyzed the count and EMT classification of CTCs detected by the CanPatrol ® platform in 195 HCC patients. The clinical relevance with other pathological features was statistically evaluated. RESULTS: CTCs were detected in 95% of the 195 HCC patients with …a range of 0–86 CTCs. Total CTCs numbers were correlated with BCLC stages, metastasis and serum AFP levels. The AUC of the ROC curve was 0.861 (95% CI: 0.782–0.940) in discriminating metastatic HCC patients with non-metastatic patients. Epithelial, hybrid and mesenchymal CTCs were found in about 53%, 83% and 57% patients, respectively. The proportion of hybrid and mesenchymal CTCs was associated with ages, BCLC stages, metastasis and AFP levels. Besides, recurrent HCC patients presented higher CTCs count and increased hybrid and mesenchymal CTCs. CONCLUSIONS: CTCs count and EMT classification are correlated with clinical stages and metastasis of HCC, suggesting that they may be potential markers for the early diagnosis of HCC metastasis and progression. Show more
Keywords: Circulating tumor cells, hepatocellular carcinoma, epithelial-mesenchymal transition, cancer metastasis
DOI: 10.3233/CBM-170315
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 487-498, 2017
Authors: Jiang, Lei | Wang, Wen-Jun | Li, Zhan-Wu | Wang, Xiao-Zhou
Article Type: Research Article
Abstract: BACKGROUND: Gastric cancer is one of the most common malignancies worldwide. Recent studies reported that Piwil3 was overexpressed in various cancers, including gastric cancer (GC). This study was intended to investigate its function and mechanism in GC progress. METHODS: Quantitative real time PCR(RT-PCR) and western blotting assays were utilized to measure mRNA and protein expression levels, respectively. SiRNA transfection was performed to suppress the expression of Piwil3. CCK-8 assay, cell invasion and migration assays were used to determine the cell proliferative, cell invasive and migratory ability. RESULTS: The expression of Piwil3 was significantly …increased in GC tissues compared with matched normal tissues. The specific siRNA significantly inhibited the protein and mRNA expressions of Piwil3, and effectively inhibited the proliferation and induced G0/G1 phase arrest in GC cells. Downregulation of Piwil3 significantly suppressed the migration and invasion of GC cells. Moreover, the downregulation of Piwil3 also significantly suppressed the tumor volumes in nude mice. Mechanism investigation showed that the downregulation of Piwil3 significantly decreased the mRNA and protein expressions of metastasis-related genes, including RhoC, MTA1, MMP2 and MMP9, and also modulated the phosphorylation levels of JAK2 and STAT3 but not their protein levels. CONCLUSIONS: These findings indicate that overexpression of Piwil3 promotes the proliferation, migration and invasion of GC cells partially through JAK2/STAT3 signal pathway. Show more
Keywords: Piwil3, gastric cancer, proliferation, metastasis, JAK2/STAT3
DOI: 10.3233/CBM-170324
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 499-509, 2017
Authors: Gou, Xun | Zhao, Xiyan | Wang, Zhengrong
Article Type: Research Article
Abstract: BACKGROUND: Long noncoding RNAs (lncRNA) have been verified to be involved in hepatocellular carcinoma (HCC) progression. However, the potential biologic function of PVT1 in HCC is not still fully known. METHODS: PVT1 and miR-214 were detected by qRT-PCR assays in HCC tissues and adjacent normal tissues. CCK8, cell colony and transwell invasion assays were performed to evaluate cell proliferation and invasion abilities. Western-blot assay was performed to detect the protein of E-cadherin and Vimentin. QRT-PCR, RNA immunoprecipitation (RIP) and chromatin immunoprecipitation (ChIP) assays demonstrated PVT1 regulated miR-214 expression. RESULTS: The results showed that …PVT1 was increased in HCC tissues and higher PVT1 expression was associated with tumor size, histological differentiation grade and advanced TNM stage. Furthermore, we revealed that PVT1 promoted cell proliferation and invasion in HCC. RIP and ChIP assays demonstrated that PVT1 significantly inhibited miR-214 expression by interacting with enhancer of zeste homolog 2 (EZH2). CONCLUSIONS: Thus, these results demonstrated that PVT1/EZH2/miR-214 regulatory pathway might serve as new target for HCC treatment. Show more
Keywords: Hepatocellular carcinoma, PVT1, enhancer of zeste homolog 2, miR-214, long non-coding RNA
DOI: 10.3233/CBM-170331
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 511-519, 2017
Authors: Chen, Jian | Yang, Li | Wang, Xiongwei
Article Type: Research Article
Abstract: BACKGROUND: MicroRNAs (miRNAs) have been demonstrated to play an important role in the development and progression of various types of cancer including glioblastoma (GBM). OBJECTIVE: The aim of this study was to investigate the expression pattern and prognostic significance of serum miR-203 in patients with GBM. METHODS: miR-203 extracted from cell culture medium and serum samples was detected by real-time PCR. The correlation between serum miR-203 expression as well as clinicopathological characteristics and patient survival was determined. RESULTS: The expression level of miR-203 was remarkably reduced in the GBM cells …and their culture medium. Serum miR-203 expression was significantly decreased in GBM patients compared with low grade glioma (LGG) patients and healthy controls. In addition, serum miR-203 discriminated GBM patients from LGG patients and healthy subjects. Chi-squared analysis showed that a significant correlation was found between low serum miR-203 expression and larger tumor size as well as lower Karnofsky Performance Scale scores. Patients with lower serum miR-203 suffered poorer overall survival (OS) and progression free survival (PFS). Multivariate analysis indicated that low miR-203 expression is an independent prognostic factor for poor OS in GBM patients. CONCLUSIONS: These data demonstrate that serum miR-203 expression might serve as a potential prognostic indicator of GBM. Show more
Keywords: Glioblastoma, miR-203, prognosis, real-time PCR
DOI: 10.3233/CBM-170335
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 521-526, 2017
Authors: Mei, Li-Li | Qiu, Yun-Tan | Huang, Meng-Bing | Wang, Wen-Jun | Bai, Jie | Shi, Zhi-Zhou
Article Type: Research Article
Abstract: miR-99a is down-regulated in esophageal squamous cell carcinoma (ESCC), however the role and underlying mechanism are still unknown. We aim to explore the role and mechanism of miR-99a down-regulation in ESCC. The expression of miR-99a in ESCC tissues and cell lines was detected by Human miRNA Microarrays and Real-time PCR. The effects of miR-99a on cell proliferation, migration and invasion were determined by Cell Counting Kit-8 (CCK-8) assay, transwell migration and invasion assay. Target gene of miR-99a were analyzed by target prediction software and validated by Real-time PCR and Western blotting assay. Our microarray results and four Gene Expression Omnibus …(GEO) datasets showed lower expression level of miR-99a in ESCC tissues. Overexpression of miR-99a using mimics significantly suppressed cell proliferation, and decreased expressions of CCND1, CCNA2 and CCNE1. We also found that enhanced miR-99a significantly inhibited migration, invasion and epithelial-mesenchymal transition (EMT) of ESCC cells, and down-regulated EMT associated transcription factor Slug, and MMPs including MMP2, MMP7 and MMP13. TargetScan predicted insulin-like growth factor 1 receptor (IGF1R) as the cadidate target gene of miR-99a, and western blotting confirmed the negative correlation between miR-99a and IGF1R. Importantly, we further found that knockdown of IGF1R also significantly inhibited the proliferation, migration, invasion and slug-induced EMT of ESCC cells, and reduced the cell cycle regulatory proteins and MMPs. In conclusion, our findings suggested that loss of miR-99a in ESCC promoted the tumor cell proliferation, migration, invasion and slug-induced EMT through activating IGF1R signaling pathway. Show more
Keywords: miR-99a, proliferation, epithelial-mesenchymal transition, insulin-like growth factor 1 receptor, esophageal squamous cell carcinoma
DOI: 10.3233/CBM-170345
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 527-537, 2017
Authors: Shi, Qin | Zhou, Zhan | Ye, Naishu | Chen, Qiaolin | Zheng, Xiuxia | Fang, Minshan
Article Type: Research Article
Abstract: BACKGROUND: MicroRNAs (miRNAs) emerge as important regulators involved in malignant progression in some tumors. MiR-181a has been found to function as a tumor suppressor in some tumors including non-small cell lung cancer (NSCLC). However, the functional role of miR-181a in NSCLC still needed to be investigated. METHODS: The expression of miR-181a were determined by qRT-PCR, the association between miR-181a and clinicopathological data were performed by chi-square test and survival analysis were evaluated by Kaplan-Meier curve and log rank test. Cell proliferation and invasion were assessed by CCK8, cell colony formation and transwell assays. Luciferase reporter …assay demonstrated that CDK1 was a target of miR-181a. Western blot assay detected the relative protein expression. RESULTS: In the study, our results showed that miR-181a was significantly down-regulated in non-small cell lung cancer (NSCLC) tissues and cell lines. MiR-181 expression levels were significantly associated with histological grade, N status and TNM stage in the patients and lower miR-181a predicted a poor prognosis in NSCLC patients. Furthermore, upregulation of miR-181a significantly suppressed the NSCLC cell proliferation, colony formation, and cell invasion capacities. Moreover, upregulation of miR-181a inhibited CyclinB1 and CyclinD1 expression in NSCLC cells. Luciferase activity assay results demonstrated CDK1 was a direct target of miR-181a and miR-181a inhibited cell proliferation by regulating the mRNA and protein levels of CDK1 in NSCLC cells. CONCLUSION: These data suggested that miR-181a plays a tumor suppressor and may be a potential therapeutic target for NSCLC patients. Show more
Keywords: Non-small cell lung cancer, miR-181a, CDK1, cell proliferation
DOI: 10.3233/CBM-170350
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 539-546, 2017
Authors: Liu, Suoning | Suo, Jian | Wang, Chunxi | Sun, Xuan | Wang, Daguang | He, Liang | Zhang, Yang | Li, Wei
Article Type: Research Article
Abstract: BACKGROUND: An overwhelming amount of evidence has emerged suggesting that dysregulated microRNAs (miRNAs) play crucial roles in tumorigenesis. OBJECTIVE: The study was to analyze tissue/serum miR-144 expression in gastric cancer and then evaluate their potential to predict the prognosis of gastric cancer. METHODS: We examined miR-144 levels in tissues and peripheral blood samples from 96 gastric cancer patients using real-time PCR. Then the association between tissue/serum miR-144 levels and clinicopathological parameters was determined. RESULTS: The expression levels of miR-144 were significantly down-regulated in the cancerous tissue and serum samples from …gastric cancer patients. Serum miR-144 was able to differentiate the gastric cancer patients from healthy controls with high accuracy. In addition, tissue and serum miR-144 levels were both associated with clinical stage and lymph node metastasis. Moreover, patients with lower tissue or serum miR-144 suffered worse 5 year overall survival and disease free survival. CONCLUSIONS: Taken together, our data support the potential clinical value of tissue and serum miR-144 as prognostic biomarkers in gastric cancer. Show more
Keywords: Biomarker, miR-144, prognosis, gastric cancer
DOI: 10.3233/CBM-170351
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 547-552, 2017
Authors: Fang, Enhao | Zhang, Xiuqing | Wang, Qi | Wang, Daoming
Article Type: Research Article
Abstract: BACKGROUND: Prostate cancer (PCa) is the most common and the second leading cause of cancer-related death among men in America. As the molecular mechanism of PCa has not yet been completely discovered, identification of hub genes and potential drug of this disease is an important area of research that could provide new insights into exploring the mechanisms underlying PCa. OBJECTIVE: The aim of this study was to identify potential biomarkers and novel drug for prostate cancer treatment. METHODS: The differentially expressed genes (DEGs) between prostate cancer and normal cells were screened using microarray …data obtained from the Gene Expression Omnibus database. Gene ontology (GO) and pathway enrichment analyses were performed in order to investigate the functions of DEGs, and the protein-protein interaction (PPI) network of the DEGs was constructed using the Cytoscape software. DEGs were then mapped to the connectivity map database to identify molecular agents associated with the underlying mechanisms of PCa. RESULTS: Totally, 359 genes (155 upregulated and 204 downregulated genes) were found to be differentially expressed between prostate cancer and normal cells. The GO terms significantly enriched by DEGs included cell adhesion, protein binding involved in cell-cell adhesion, response to BMP, extracellular region and extracellular region part. KEGG pathway analysis showed that the most significant pathways included cell adhesion molecules (CAMs) and TGF-beta signaling pathway. The PPI network of up-regulated DEGs and down-regulated DEGs were established, respectively. While CDH1 , BMP2 , NKX3-1 , PPARG and PRKAR2B were identified as the hub genes in the PPI network. CONCLUSIONS: The BMP2 , PPARG and PRKAR2B genes may therefore be potential biomarkers in the treatment of PCa. Additionally, the small molecular agent phenoxybenzamine may be a potential drug for PCa. Show more
Keywords: Prostate cancer, bioinformatics analysis, differently expressed genes, hub genes, therapeutic agent
DOI: 10.3233/CBM-170362
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 553-561, 2017
Authors: Kalantari, Elham | Asadi Lari, Mohammad Hossein | Roudi, Raheleh | Korourian, Alireza | Madjd, Zahra
Article Type: Research Article
Abstract: BACKGROUND: Gastric carcinoma is the third most common malignancy and is one of the main causes of cancer deaths worldwide. Cancer stem cells (CSCs) are a subpopulation of tumour cells capable of self-renewal and differentiation, likely responsible for the initiation, recurrence, metastasis and chemo/radio-resistance. OBJECTIVE: This study was conducted to evaluate the expression patterns and clinicopathologic significance of putative CSC markers, Lgr5 and DCLK1, in gastric carcinoma. METHOD: The expression levels of Lgr5 and DCLK1 were examined in a well-defined series of gastric carcinoma tissues, including 75 (80%) from intestinal and 19 (20%) from …diffuse subtypes, using tissue microarray (TMA). In addition, the correlation of the expression of these markers with clinicopathological factors was explored. RESULTS: Higher expressions of Lgr5 and DCLK1 were mainly detected in intestinal subtypes of gastric carcinomas compared to diffuse subtypes (P = 0.005 and P = 0.050, respectively). We also found a higher expression of Lgr5 and DCLK1 more frequently in well-differentiated gastric carcinoma cases (P < 0.001 and P = 0.007). The combined analysis demonstrated that the co-expression of Lgr5 and DCLK1 (Lgr5 High /DCLK1 High ) was more common in intestinal subtypes (P = 0.025) and well-differentiated gastric carcinoma samples (P < 0.001). Interestingly, there was a significant correlation between Lgr5 High /DCLK1 High phenotype and early-stage gastric carcinoma specimens (P = 0.045). CONCLUSION: Our findings indicated that the Lgr5 High /DCLK1 High expression pattern may be considered as a signature phenotype for intestinal subtypes of gastric carcinoma. Show more
Keywords: Gastric carcinoma, cancer stem cells, Lgr5, DCLK1
DOI: 10.3233/CBM-170383
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 563-573, 2017
Authors: Luan, Suxian | Mu, Meiling | Sun, Liangzhi
Article Type: Research Article
Abstract: OBJECTIVE: Selfheal has been used for many years in hyperprolactinemia induced galactorrhea, menstrual disorders, and dysgenesis with satisfactory curative effect. However, its mechanism is still unclear. This study intended to investigate the effect of selfheal extract on hyperprolactinemia in vivo and in vitro, in order to elucidate its mechanism of anti-hyperprolactinemia. PATIENTS AND METHODS: Hyperprolactinemia rat model was established. High dose (28.8 g/(kg⋅ d)), middle dose (14.4 g/ (kg⋅ d)), and low dose (7.2 g/(kg⋅ d)) of selfheal extract were used to treat the model to observe impact on serum estradiol (E2), …progesterone (P), prolactin (PRL), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels. Three cell lines MMQ, GH3, and PC12 were applied to investigate selfheal extract effect on PRL secretion, dopamine D2 receptor, and dopamine transporter (DAT). RESULTS: High and middle dose of selfheal extract significantly reduced PRL level in hyperprolactinemia rat compared with model group (P < 0.01). Compared with normal control, 5 mg/ml and 10 mg/ml selfheal extract obviously inhibited PRL secretion in MMQ cells that high expressed D2 receptor after 24 hours (P < 0.01), but did not affect PRL secretion in GH3 cells lack of D2 receptor. 8 mg/ml selfheal extract markedly suppressed D2 receptor and DAT expression in PC12 cells that strongly expressed D2 receptor and DAT (P < 0.01). CONCLUSIONS: Selfheal extract treated hyperprolactinemia through dopamine D2 receptor with significant effect. Show more
Keywords: Selfheal extract, hyperprolactinemia, PRL, dopamine D2 receptor, DAT
DOI: 10.3233/CBM-170454
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 575-580, 2017
Authors: Xu, Zhi-Hong | Liu, Cai-Hong | Hang, Jun-Biao | Gao, Bei-Li | Hu, Jia-An
Article Type: Research Article
Abstract: Tyrosine kinase inhibitors (TKIs), a novel group of target-specific anti lung cancer drugs, have recently been found to resistant to some NSCLC cells which have the T790M EGFR mutation. However, recent investigations on the therapies of resistance to EGFR-TKIs are very limited. Therefore, it is important to develop more effective therapies to reverse EGFR-TKIs resistance. In our present study, erlotinib was used as the TKIs drug and the effects of the erlotinib on cell growth were evaluated. Cell viability and concentration dependent studies were performed using HCI-H1975 and HCI-H1299 cells alone with erlotinib, respectively. Further combined with rituximab, the results …showed that erlotinib and rituximab were significantly inhibited the cell growth. Furthermore, the combination of erlotinib and rituximab greatly decreased the expression of p-mTOR and p-EGFR. Additional results from western blotting and immunofluorescence assays demonstrated that the accumulation of rictor was also decreased on MAM. Thus, all these results suggested that EGFR-TKIs combined with CD20 mono-antibody significantly decrease the cell growth of H1975 cells and H1299, with T790M EGFR mutation, and inhibit the localization of the key mTOR pathway proteins to MAM. So, it may be a promising strategy for overcoming EGFR TKI resistance in NSCLC patients. Show more
Keywords: Rituximab, tyrosine kinase inhibitors, ER-membrane, NSCLC cells
DOI: 10.3233/CBM-170575
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 581-588, 2017
Authors: Xia, Hong-Liang | Lv, Yao | Xu, Chun-Wei | Fu, Ming-Cui | Zhang, Ting | Yan, Xiang-Ming | Dai, Shu | Xiong, Qian-Wei | Zhou, Yun | Wang, Jian | Cao, Xu
Article Type: Research Article
Abstract: Neuroblastoma is a brain malignancy of childhood and accounts for 7–10% of childhood cancers, leading to approximately 15% of pediatric cancer deaths. MicroRNAs (miRNAs) are a family of short (about 18–25 nucleotides), noncoding and single stranded endogenous RNAs, which complementarily bind to the 3’ untranslated regions of their target genes. Recently, glutamine metabolism has been recognized as an important nutrition source for tumor cells, and hence targeting glutamine metabolism could benefit to development of anti-cancer agents. In this study, we investigate the roles of miR-513c in human neuroblastoma. We report miR-513c is significantly downregulated in human neuroblastoma tissues compared with …their adjacent normal tissues. Moreover, miR-513c is significantly downregulated in neuroblastoma cell lines compared with normal neuroblast cells. Overexpression of miR-513c suppresses neuroblastoma cells’ migration, invasion, and proliferation. We demonstrate the glutaminase (GLS) is a direct target of miR-513c in human neuroblastoma cells. In addition, we found restoration of GLS expression recovered the neuroblastoma cells’ migration, invasion, and proliferation. In summary, this study illustrates a miR-513c mediated neuroblastoma cells suppression, providing a new aspect on the miRNA-based therapeutic approach for the treatments of neuroblastoma. Show more
Keywords: MiR-513c, neuroblastoma, glutaminase, migration, invasion, proliferation
DOI: 10.3233/CBM-170577
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 589-596, 2017
Authors: Sun, Yi | Li, Li | Xing, Shigang | Pan, Yinghua | Shi, Yunxiang | Zhang, Linghua | Shen, Qiang
Article Type: Research Article
Abstract: Studies have shown that microRNAs (miRNAs) can promote or suppress tumor growth and therefore act as targets for cancer therapy. Hsa-miR-503-5p, a mature miRNA derived from 5’ ends of pre-miR-503, has been proved to regulate cell proliferation, transformation, migration and invasion. However, the biological function of miR-503-3p derived from 3’ ends of pre-miR-503 has never been reported. In current study, we found that miR-503-3p inhibits lung cancer cell viability and induces cell apoptosis. To better understand the molecular mechanism underlying the miR-503-3p participating in this process, PCR array and RNA-sequencing (RNA-seq) were performed and some differential expression genes were discovered …between NC and miR-503-3p treated groups. Biological interaction network showed that p21 and CDK4 are the most important proteins involving miR-503-3p signal pathway. Dual-luciferase assay results shown miR-503-3p directly regulates the expression of p21 by targeting 3’-UTR of its mRNA. These results shed light on the potential roles of miR-503-3p, indicating that it may act as an anti-oncogene factor to inhibit lung cancer cell viability. Show more
Keywords: Lung cancer, miR-503-3p, apoptosis, p21
DOI: 10.3233/CBM-170585
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 597-608, 2017
Authors: Liu, Li-Wei | Yang, Ming-Ya | Zhou, Min | Li, Jia-Jia | Liu, Bo | Pan, Yue-Yin
Article Type: Research Article
Abstract: OBJECTIVE: To investigate the improvement of cytotoxicity of autologous CIKs from patients with breast cancer to MCF-7 cells by suppressed PD-1 expression. METHODS: The Lentiviral Vector/PD-1 carrying the gene that can suppressed PD-1 was transferred to CIK cells from patients with breast cancer to inhibit PD-1 expression. The PD-1 protein were detected by RT-PCR and Western blot. The positive PD-1 of CIKs and PD-L1 of MCF-7 cells were detected by FCM, and cytotoxicity of CIKs to MCF-7 was assayed by CCK-8. RESULTS: The PD-1 positive CIKs with Lentiviral Vector/PD-1 transferred from patients with breast …cancer were 16.02%, 14.36% and 14.64% at 14 th , 21 st and 28 th day, obviously inhibited as compared to 50.54%, 74.50% and 73.36% in CIKs without transinfection (P < 0.05); the Lentiviral Vector/PD-1 decreased the PD-1 mRNA levels in CIK cells, and Lentiviral Vector/PD-1-transferred CIKs had lower PD-1 expression; CCK-8 detection showed that at 14 th day, the cytotoxicity rates of CIKs with blank plasmids and those with PD-1 transfection to MCF-7 cells were 58.78% and 68.14%, respectively. CONCLUSION: MCF-7 cells have a strong PD-L1 expression at its surface, and inhibition of PD-1 expression can improve the cytotoxicity of CIK cells. Show more
Keywords: CIKs, MCF-7 cells, PD-1, PD-L1, cytotoxicity
DOI: 10.3233/CBM-170588
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 609-615, 2017
Authors: Liu, Guang-Wei | Qin, Zhao-Min | Shen, Qin-Hai
Article Type: Research Article
Abstract: OBJECTIVE: It is crucially important to discover the relationships between genes and microRNAs (miRNAs) in cancer. Thus, we proposed a combined bioinformatics method integrating Pearson’s correlation coefficient (PCC), Lasso, and causal inference method (IDA) to identify the potential miRNA targets for stomach adenocarcinoma (STAD) using Borda count election. MATERIALS AND METHODS: Firstly, the ensemble method integrating PCC, IDA, and Lasso was used to predict miRNA targets. Subsequently, to validate the performance ability of this ensemble method, comparisons between verified database and predicted miRNA targets were implemented. Pathway analysis for target genes in the top 1000 miRNA-mRNA interactions …was implemented to discover significant pathways. Finally, the top 10 target genes were identified based on predicted times > 3. RESULTS: The ensemble approach was confirmed to be a feasible method to predict miRNA targets The 527 target genes of the top 1000 miRNA-mRNA interactions were enriched in 21 pathways. Of note, cell adhesion molecules (CAMs) was the most significant one. The top 10 target genes were identified based on predicted times > 3, such as GABRA3, CSAG1 and PTPN7. These targets were all predicted by 4 times. Moreover, GABRA3 and CSAG1 were simultaneously targeted by miRNA-105-1, miRNA-105-2, and miRNA-767. Significantly, among these top 10 targets, PTPN7 and GABRA3-miRNA interactions owned the highest correlation with 691. CONCLUSION: The combined bioinformatics method integrating PCC, IDA, and Lasso might be a valuable method for miRNA target prediction, and dys-regulated expression of miRNAs and their potential targets might be prominently involved in the pathogenesis of STAD. Show more
Keywords: Stomach adenocarcinoma, ensemble method, miRNA targets
DOI: 10.3233/CBM-170595
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 617-625, 2017
Authors: Wei, Yi-Sheng | Zhou, Ya-Guang | Wang, Guo-Ying | Liang, Zhi-Hua | Luo, Min-Rui | Yang, Tian-Ai | Huang, Jun
Article Type: Research Article
Abstract: BACKGROUND AND OBJECTIVE: The association of chemotherapy-associated hemoglobin and survival of colorectal cancer (CRC) receiving adjuvant chemotherapy is uncertain. We sought to explore the prognostic value of chemotherapy-associated hemoglobin in CRC receiving adjuvant chemotherapy and the best cut point affecting prognosis. METHODS: Three hundred and twenty stage II and III CRC patients receiving adjuvant FOLFOX chemotherapy from March 2003 to March 2012 were enrolled. The associations between chemotherapy-associated hemoglobin (the absolute levels of post-chemotherapy) or chemotherapy-associated hemoglobin change (change between the pre- and post-chemotherapy hemoglobins) and disease free survival (DFS) or overall survival (OS) of CRC, …and the best cut point were investigated. RESULTS: Log rank test showed the best cut points for chemotherapy-associated hemoglobin and chemotherapy-associated hemoglobin change were respectively 90 g/L, 30 g/L. Cox regression model showed chemotherapy-associated hemoglobin < 90 g/L was the independent prognostic factor for DFS (HR, 2.221; 95% CI = 1.157–4.262), OS (HR, 2.058; 95% CI = 1.009–4.197), respectively, but no association of chemotherapy-associated hemoglobin change ⩾ 30g/L and DFS (HR, 2.063; 95% CI = 0.929–4.583), OS (HR, 1.386; 95% CI = 0.553–3.471) was found. CONCLUSIONS: Chemotherapy-associated hemoglobin < 90 g/L has a significant prognostic value in CRC receiving adjuvant chemotherapy, which is a significant biomarker in the individualized management and may suggest the simple indication for the treatment of anemia in adjuvant chemotherapy in CRC. Show more
Keywords: Adjuvant chemotherapy, colorectal cancer, hemoglobin, disease free survival, overall survival
DOI: 10.3233/CBM-170601
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 627-635, 2017
Authors: Majek, Pavel | Pecankova, Klara | Cermak, Jaroslav | Gasova, Zdenka | Prochazka, Bohumir | Dyr, Jan E.
Article Type: Research Article
Abstract: BACKGOUND: It has been indicated in plasma proteomic studies on different myelodysplastic syndrome (MDS) cohorts that alpha-2-HS-glycoprotein could be a promising MDS biomarker candidate. OBJECTIVE: The goal of this work was to estimate alpha-2-HS-glycoprotein (AHSG) plasma levels and its biomarker value in the low- and high-risk subgroups of MDS patients. METHODS: The level of AHSG was estimated for 115 plasma samples using ELISA. RESULTS: The AHSG plasma level was found to be decreased significantly (p = 2.59 × 10 - 7 …) in MDS patients (515 ± 58 μ g/ml) when compared to healthy controls (579 ± 64 μ g/ml). Pearson and Spearman correlation analyses showed that age is the principal factor affecting the AHSG plasma level, rather than risk/diagnosis in MDS. CONCLUSIONS: In this work we demonstrate that although the total plasma level of AHSG is decreased in myelodysplastic syndrome patients, in particular in advanced MDS, that decrease correlates more strongly with age than with diagnosis within our studied cohort. Thus, according to the AHSG data gathered so far, AHSG total plasma level does not seem to be a suitable MDS biomarker, but its particular proteoforms should be considered for the next steps in MDS research. Show more
Keywords: AHSG, alpha-2-HS-glycoprotein, MDS, myelodysplastic syndrome
DOI: 10.3233/CBM-170638
Citation: Cancer Biomarkers, vol. 20, no. 4, pp. 637-639, 2017
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]